EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease

Gorka Larrinaga iD, Jon Danel Solano-Iturri, Inés Arrieta-Aguirre, Asier Valdivia iD, David Lecumberri iD, Ane Miren Iturregui iD, Charles H Lawrie iD, María Armesto iD, Juan F Dorado iD, Caroline E Nunes-Xavier iD, Rafael Pulido iD, José I López iD und 1 weitere

Biomolecules · 2025

DOI: 10.3390/biom15030387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Gorka Larrinaga und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Receptors, G-Protein-Coupled. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza, Basque Government, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in the management of advanced clear cell renal cell carcinoma (ccRCC), robust biomarkers for prognosis and therapeutic response prediction remain elusive. Dysregulation of the intrarenal renin–angiotensin system (RAS) has been implicated in renal carcinogenesis but little explored, particularly regarding biomarker discovery and therapeutic innovation. Consequently, this study investigates the immunohistochemical expression and clinical relevance of the Mas-related G-protein-coupled receptor D (MrgD) in patients with ccRCC who developed metastatic disease (mccRCC). A cohort of 132 patients treated between 2008 and 2018 with nephrectomy and tyrosine kinase inhibitor (TKI)-based sequential therapy was analyzed. Treatment response was assessed using both the MASS and RECIST scoring systems. High MrgD expression in primary tumors was significantly associated with larger size, advanced stage, higher histological grade, and worse overall survival. Among 81 patients with metachronous metastases, high MrgD expression independently predicted shorter disease-free survival. High MrgD staining intensity correlated with poorer TKI responses in first-line therapy but improved outcomes with second-line mTORC1 inhibitors. These findings suggest that MrgD may be a useful biomarker of RAS linked to tumor aggressiveness in ccRCC. MrgD holds potential for identifying high-risk patients and guiding treatment selection in advanced disease. Further research is needed to unlock its clinical potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsReceptors, G-Protein-CoupledHumansMaleFemaleMiddle AgedAgedPrognosisBiomarkers, TumorNeoplasm MetastasisProtein Kinase InhibitorsAdultAged, 80 and overNephrectomyGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

AlamandineMrgDbiomarkerclear cell renal cell carcinomaimmunohistochemistrymetastaticprognosticrenin–angiotensin systemtyrosin kinase inhibitors

Substanzen

Biomarkers, TumorReceptors, G-Protein-CoupledProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Nursing, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
  • Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
  • Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
  • Pathology Department, Cruces University Hospital, 48903 Barakaldo, Spain.
  • Department of Cellular Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
  • Department of Urology, Cruces University Hospital, 48903 Barakaldo, Spain.

ORCID-Profile: Gorka Larrinaga, Asier Valdivia, David Lecumberri, Ane Miren Iturregui, Charles H Lawrie, María Armesto, Juan F Dorado, Caroline E Nunes-Xavier, Rafael Pulido, José I López, Javier C Angulo

Förderung

  • Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza
  • Basque Government
  • Instituto de Salud Carlos III
  • European Union

Zitieren

APA

Larrinaga, G., Solano-Iturri, J. D., Arrieta-Aguirre, I., Valdivia, A., Lecumberri, D., Iturregui, A. M., Lawrie, C. H., Armesto, M., Dorado, J. F., Nunes-Xavier, C. E., Pulido, R., López, J. I., & Angulo, J. C. (2025). Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease. Biomolecules. https://doi.org/10.3390/biom15030387

Vancouver

Larrinaga G, Solano-Iturri JD, Arrieta-Aguirre I, Valdivia A, Lecumberri D, Iturregui AM, et al. Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease. Biomolecules. 2025. doi:10.3390/biom15030387

BibTeX
@article{Larrinaga2025,
  author = {Larrinaga, Gorka and Solano-Iturri, Jon Danel and Arrieta-Aguirre, Inés and Valdivia, Asier and Lecumberri, David and Iturregui, Ane Miren and Lawrie, Charles H and Armesto, María and Dorado, Juan F and Nunes-Xavier, Caroline E and Pulido, Rafael and López, José I and Angulo, Javier C},
  title = {Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15030387}
}
Kostenlos starten →